Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q3 2024 · 10-Q
Revenue$25.58M$25.58M+31.2% vs Q3 2023 Net Income$1.88M$1.88MN/M vs Q3 2023 EPS Diluted$0.02$0.02N/M vs Q3 2023 Gross Profit$16,240,000+35.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived$3,495,000+782.6% Margins · derivedGross margin63.5%+2.1 pt vs Q3 2023
Operating margin6.3%+12.1 pt vs Q3 2023
Net margin7.3%+12.3 pt vs Q3 2023
ended Sep 30, 2024 · filed Oct 31, 2024 · 31 d after period end